Articles written by STAT - Benzinga

STAT+: M&A is back, but nothing in biotech is neat or simple

|This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox. Biotech mood check: Happy Two

Trump order targeting 'DEI-based standards' in medical accreditation sparks concern

|A new Trump administration executive order targeting the use of “DEI-based standards” to accredit universities could shake up the small club of groups that set standards for the nation’s medical

Sedative 'dex' is replacing 'tranq' in illegal drug supply and causing excruciating withdrawal

|The era of “tranq” may be ending. But tranq, as the powerful veterinary tranquilizer xylazine is known in the illicit drug supply, is being replaced at least in part by a dangerous new sedative:

Opinion: RFK Jr.'s synthetic dye bans miss a much bigger problem

|As a professor of physiology, I study how scientific evidence gets translated, sometimes clumsily, from the lab to real life. Whether it’s scaling dietary supplements to humans or using biomimicry to mitigate

Opinion: Why NIH's policy on grants to universities with DEI programs is not cause for widespread alarm

|The recent news that the NIH will require universities to certify their diversity programs comply with federal civil rights law created understandable anxiety in the academic community. The confusion is partly due to

NIH cancels participation in Safe to Sleep campaign that decreased infant deaths

|WASHINGTON — The Trump administration has cancelled federal participation in Safe to Sleep, a 30-year campaign to prevent babies from dying in their sleep, STAT and the Medill News Service have learned. The

STAT+: Lack of access to antibiotics for drug-resistant infections often blamed on poor care, study says

|Only 6.9% of people with drug-resistant infections in eight large, low- and middle-income countries received an appropriate antibiotic in 2019 and the lack of access was largely attributed to insufficient care, according

STAT+: Study: Lack of access to antibiotics for drug-resistant infections often blamed on poor care

|Only 6.9% of people with drug-resistant infections in eight large, low- and middle-income countries received an appropriate antibiotic in 2019 and the lack of access was largely attributed to insufficient care, according

STAT+: Doctors didn't catch AI's mistakes. What does that mean for human-in-the-loop?

|You’re reading the web edition of STAT’s AI Prognosis newsletter, our subscriber-exclusive guide to artificial intelligence in health care and medicine. Sign up to get it delivered in your inbox

STAT+: GOP Senator Collins says Trump's layoffs of scientists, cuts to biomedical research 'must be reversed'

|WASHINGTON — Sen. Susan Collins (Maine), the Republican chair of the Senate Appropriations Committee, is rebuking the Trump administration for cutting federal biomedical research funding, cancelling grants, and

STAT+: Collins and fellow GOP senators speak out in opposition to Trump's cuts to biomedical research

|WASHINGTON — There was broad bipartisan support at a Senate hearing Wednesday to reverse course on the Trump administration’s cuts to federally funded biomedical research. Sen. Susan Collins (Maine), the

STAT+: Pharmalittle: We're reading about Makary rejecting a reorganization, pharma lobbying against PBMs, and more

|Hello, everyone, and how are you today? We are doing just fine, thank you, especially since the middle of the week is upon us. After all, we have made it this far so we are determined to hang on for another couple of

Pfizer CEO thinks pharma tariffs won't be applied equally

|Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning, let’s get into all the updates from a busy earnings season so

Perinatal factors could play a role in heart health across the life span

|Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Usha Lee McFarling filling in for Theresa this morning, and very excited to hear about her

STAT+: Novartis to buy kidney-focused biotech built around Nobel-winning discovery for $800 million

|Novartis said Wednesday it would buy Regulus Therapeutics and its experimental kidney drug for $800 million upfront. The immediate payout is more than triple Regulus’s current market cap. Novartis could

STAT+: NIH plans to reduce animal testing in federally funded research

|In a significant move, the U.S. National Institutes for Health said it would reduce its reliance on animals in federally funded research and instead prioritize investment in human-based alternatives, the second time this

STAT+: Health systems in limbo as HHS stays quiet on nondiscrimination rules for AI, algorithms

|It’s been a year since the federal government clarified that technology tools used in health care shouldn’t discriminate against patients based on protected traits such as age, sex, race, and disability. A

Will the FDA approve the first new drug to help people quit smoking in 20 years?

|Nearly 12% of Americans still smoke cigarettes, the leading cause of preventable death nationwide. Yet there are only two medications authorized by the Food and Drug Administration to help them quit — the more

Opinion: The end of the medical school cadaver lab?

|In the 19th century, medical schools were desperate for corpses from which their students could learn. Grave robbers would sell bodies; sometimes, janitors, students, or even instructors would themselves dig up

8 possible indicators of how RFK Jr.'s HHS will handle vaccine policy

|It’s been less than three months since Robert F. Kennedy Jr. was sworn in as the U.S. health secretary and already there have been many signs the longtime critic of vaccines intends to use his extensive powers